secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2026-08-05T20:03:09+00:00
Accession:  0001650664-26-000082
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine Q2 net loss narrows to $18.2M; EDIT-401 on track for CTN submission
--------------------------------------------------------------------------------

- Net loss $18.2M ($0.15/sh) vs $53.2M ($0.63/sh) in Q2 2025; collaboration revenue up to $11.9M.
- Cash $211.6M as of June 30, 2026, up from $146.6M; cash runway into H2 2028.
- EDIT-401 preclinical data shows ~90% mean reduction in LDL-C, Lp(a), ApoB in NHPs; CTN submission planned this month.
- Phase 1/2 trial for HeFH to start; data update expected Q1 2027.
- Board: Elliott Levy resigned; Patrick Ellinor appointed as independent director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000082/0001650664-26-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000082/edit-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001650664-26-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer